Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | MIF | P14174 | 5/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | CD74 | P04233 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | TNIK | Q9UKE5 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31667438 | 0.86 | MIF (0.71) | POLBMIFCD74MEN1KMT2A | |
| SCHEMBL18805706 | 0.85 | MIF (0.62) | POLBMIFNPC1CD74MEN1 | |
| SCHEMBL34475640 | 0.82 | POLB (0.52) | POLBMIFNPC1CD74MEN1 | |
| SCHEMBL31667303 | 0.81 | POLB (0.42) | POLBMIFCD74MEN1KMT2A | |
| SCHEMBL32674495 | 0.80 | MIF (0.59) | POLBMIFNPC1CD74MEN1 | |
| SCHEMBL31667267 | 0.79 | POLB (0.51) | POLBMIFNPC1CD74MEN1 | |
| SCHEMBL20725151 | 0.78 | MIF (0.76) | POLBMIFCD74MEN1KMT2A | |
| SCHEMBL31667148 | 0.77 | POLB (0.54) | POLBMIFNPC1CD74MEN1 | |
| SCHEMBL18805695 | 0.77 | IDO1 (0.72) | POLBMIFCD74KMT2AALDH1A1 | |
| SCHEMBL32674487 | 0.76 | MIF (0.58) | POLBMIFCD74MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | SIRONAX LTD (KY) | 2026-03-19 | — | — | US | disclosed |
| EP-4590674-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd (KY) | 2025-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | NAMPT, NNMT, SARM1 | POLB 1690/4885MIF 4403/4885NPC1 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.